Skip to main content
SpringerLink
Log in

Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM

  • Letter
  • Published:
Advances in Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kawaguchi Y, Miyamoto S, Hajika Y, et al. Efficacy of IDegLira versus IDegAsp therapy in patients with type 2 diabetes: a randomized crossover study by isCGM. Adv Ther. 2022;39(6):2688–700.

    Article  Google Scholar 

  2. Draznin B, Aroda VR, Bakris G, et al. 7. Diabetes technology: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S97–S112.

    Google Scholar 

  3. Bradley C, Gamsu DS. Guidelines for encouraging psychological well-being: report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet Med. 1994;11(5):510–6.

    Article  CAS  Google Scholar 

  4. Ishii H. Development and psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire. J Med Econ. 2012;15(3):556–63.

    Article  Google Scholar 

  5. Galasso S, Facchinetti A, Bonora BM, et al. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study. Nutr Metab Cardiovasc Dis. 2016;26(12):1112–9.

    Article  CAS  Google Scholar 

  6. Oe Y, Nomoto H, Nakamura A, et al. Switching from insulin degludec plus dipeptidyl peptidase-4 inhibitor to insulin degludec/liraglutide improves glycemic variability in patients with type 2 diabetes: a preliminary prospective observation study. J Diabetes Res. 2022;2022:5603864.

    Article  Google Scholar 

  7. Miya A, Nakamura A, Miyoshi H, et al. Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: a randomized controlled trial. J Diabetes Investig. 2018;9(1):119–26.

    Article  CAS  Google Scholar 

  8. Persano M, Nollino L, Sambataro M, et al. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy. Eur Rev Med Pharmacol Sci. 2021;25(2):923–31.

    CAS  Google Scholar 

Download references

Acknowledgements

Funding

No funding or sponsorship was received for this study or publication of this article.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions

Nomoto H had the idea for the article. Oe Y and Nomoto H wrote the manuscript. Miya A, Kameda H, Cho KY, Nakamura A, Miyoshi H, and Atsumi T critically revised the manuscript.

Disclosures

This study received no specific financial support. Nakamura A has obtained research support from Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim Co., Kissei Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd. Cho KY has received honoraria for lectures from Eli Lilly Japan K.K. Miyoshi H has received honoraria for lectures from Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Co., MSD K.K., Novo Nordisk Pharma Ltd., Kowa Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ono Pharmaceutical Co., Ltd., and Sanofi; and has received research funding from Astellas Pharma Inc., Daiichi Sankyo Co., Sumitomo Dainippon Pharma Co. Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Co., Novo Nordisk Pharma, Kowa Pharmaceutical Co., Ltd., Abbott Japan Co., Nippon Boehringer Ingelheim Co., Ono Pharmaceutical Co., Ltd., LifeScan Japan Inc., and Taisho Pharmaceutical Co., Ltd. Atsumi T has received research grants from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co., Ltd. Pfizer Inc., Alexion Inc., Ono Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.; speaking fees from Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., AbbVie Inc., Eisai Co. Ltd., Daiichi Sankyo Co., Ltd., Bristol-Myers Squibb Co., UCB Japan Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., and Taiho Pharmaceutical Co., Ltd.; and fees for consultancies from AstraZeneca plc., Medical & Biological Laboratories Co., Ltd., Pfizer Inc., AbbVie Inc., Ono Pharmaceutical Co. Ltd., Novartis Pharma K.K., and Nippon Boehringer Ingelheim Co., Ltd. Oe Y, Nomoto H, Miya A and Kameda H have no conflicts of interest to declare.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. The original study was registered with the University Hospital Medical Information Network (UMIN) (registration number UMIN 000039460) and approved by the Institutional Review Board of Hokkaido University Hospital Clinical Research and Medical Innovation Center (019-0293).

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N-15, W-7, Kita-ku, Sapporo, 060-8638, Japan

    Yuki Oe, Hiroshi Nomoto, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, Hideaki Miyoshi & Tatsuya Atsumi

  2. Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan

    Kyu Yong Cho

Authors
  1. Yuki Oe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Nomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aika Miya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiraku Kameda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyu Yong Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akinobu Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideaki Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tatsuya Atsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Nomoto.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oe, Y., Nomoto, H., Miya, A. et al. Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM. Adv Ther 40, 383–386 (2023). https://doi.org/10.1007/s12325-022-02327-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-022-02327-7

Keywords

Search

Navigation